Literature DB >> 23233241

Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.

James Greig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23233241     DOI： 10.1007/s40261-012-0044-y

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  6 in total

Review 1.  Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection.

Authors:  P N Wiegand; D Nathwani; M H Wilcox; J Stephens; A Shelbaya; S Haider
Journal:  J Hosp Infect       Date:  2012-04-11       Impact factor: 3.926

2.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

3.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

4.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

5.  Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Authors:  Oliver A Cornely; Mark A Miller; Thomas J Louie; Derrick W Crook; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

6.  Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.

Authors:  David Alexander Sclar; Linda M Robison; Ambartsum M Oganov; Jennifer M Schmidt; Kurt A Bowen; Leigh V Castillo
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859
  6 in total
  1 in total

1.  Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.

Authors:  David Alexander Sclar; Linda M Robison; Ambartsum M Oganov; Jennifer M Schmidt; Kurt A Bowan; Leigh V Castillo
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.